MGNX · MacroGenics, Inc.

MacroGenics’ Q1 2026 results reflect a strategic pivot toward financial sustainability and pipeline focus. The $5.3M improvement in net loss—driven primarily by a $4.7M reduction in R&D expenses following the discontinuation of vobramitamab duocarmazine—was partially offset by a $4.1M increase in cost of manufacturing services due to higher external client production volume. Revenue growth of 57% YoY was underpinned by strong performance across two lines: contract manufacturing revenue more than doubled to $14.1M (from $6.2M), and royalty revenue from ZYNYZ rose to $6.2M (from $0.4M), though collaborative revenue fell sharply to $0.6M (from $6.6M). Management explicitly attributes this shift to the company’s realignment away from internal manufacturing and toward external partnerships and royalty monetization. The $122.5M divestiture to Bora—paired with the $60.0M Sagard royalty transaction—represents a deliberate capital strategy to secure non-dilutive funding while shedding fixed-cost infrastructure. With $154.2M in cash as of March 31, 2026—and excluding the $60.0M already received and the $122.5M pending—the company projects its cash runway extends through 2028, contingent on closing both transactions. This liquidity profile supports continued advancement of its ADC pipeline: MGC026 and MGC028 remain on track for clinical data readouts in 2026, and the IND filing for MGC030 is slated for Q3. Importantly, the LINNET study update signals disciplined portfolio management—halting development in platinum-resistant ovarian cancer due to unmet response thresholds while pursuing a lower-dose cohort in clear cell gynecologic cancer to improve safety. Collectively, these actions reinforce a clear strategic narrative: de-risking operations, preserving capital, and concentrating resources on high-potential clinical assets.